Ovarian Cancer

News Ovarian Cancer

• Novel gene drives development of different types of ovarian cancer

  Researchers at Mayo Clinic Cancer Center have identified a novel gene that can contribute to a woman's susceptibility for developing ovarian cancer. Researchers identified the gene, called HNF1B, through large-scale analysis of more than 16,000 women with ovarian cancer and more than 26,000 healthy more

• GATC Biotech conducts research to detect cancer in women

  GATC Biotech has started research on early detection of breast and ovarian cancer with the goal of developing a test to identify tumor markers present in blood and link these markers to the presence of cancer. As a partner of the research project EpiFemCare, GATC Biotech will manage sample processin more

• IXICO and PsiOxus Therapeutics win significant funding from government-backed Biomedical Catalyst

  Imperial Innovations Group plc announced that two of its portfolio companies have won significant funding from the government-backed Biomedical Catalyst Awards. IXICO and PsiOxus will receive £2.1m and £1.7m respectively to accelerate the translation of scientific ideas into commercial propositions. more

White papers Ovarian Cancer

• Quantification of BRCA1 Expression Level Using Standard RT-PCR Reagents - a Sensitive Method for the Detection of Low Amounts of Transcripts
  

  Mutations in the breast cancer susceptibility gene, BRCA1, occur in the majority of families with multiple members affected with breast or ovarian cancer. Women who inherit a BRCA1 mutation have 40%-80% risk of developing breast cancer or ovarian cancer. However, up to 90% of breast cancers are sporadic, and mutations in BRCA1 seem to be a rare event in sporadic breast tumors. more

• Analysis of the DNA Methylation Patterns at the BRCA1 CpG Island
  

  Germ-line alterations of the BRCA1 gene confer a lifetime risk of 40% for ovarian cancers and of 40%-80% for ­breast cancers. It is likely that BRCA1 acts as a tumor suppressor gene. BRCA1 involvement in breast cancers does not seem to be restricted to familial cancers. Despite the absence of somatic mutations in the breast tissues, a down regulation of BRCA1 expression is associated with malignancy in human sporadic breast cancers. more

• Rapid High-Throughput Methylation Analysis Using the LightCycler® 480 System
  

  The LightCycler® 480 Instrument is a versatile platform for molecular studies. We assessed the performance of the instrument combined with the LightCycler® 480 High Resolution Melting Master mix for DNA methylation analysis using the methylation-sensitive high resolution melting (MS-HRM) methodology. This proved to be a robust platform for performing MS-HRM experiments, allowing rapid and high-throughput studies of DNA methylation. more

Publications Ovarian Cancer

• Antitumor effects and mechanisms of dendritic cells stimulated by sCD40L on ovarian cancer cells in vitro

  Zhang ZM, Yang XM, Zhang C, Zhang MJ, Li X, Zhang FH, Kang S, Wang SJ, Shan BE more

• Antiproliferative Homoisoflavonoids and Bufatrienolides from Urginea depressa

  Investigation of the South African plant Urginea depressa Baker (Asparagaceae Juss.) for antiproliferative activity against the A2780 ovarian cancer cell line led to the isolation of the six new homoisoflavonoids urgineanins A–F (1–6), the two known bufatrienolides 7 and 9, and the new bufatrienolid more

• TNRC9 Downregulates BRCA1 Expression and Promotes Breast Cancer Aggressiveness

  Although the linkage between germline mutations of BRCA1 and hereditary breast/ovarian cancers is well established, recent evidence suggests that altered expression of wild-type BRCA1 might contribute to the sporadic forms of breast cancer. The breast cancer gene trinucleotide-repeat-containing 9 (T more

Market studies Ovarian Cancer

• Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020”. The report is an essential source of information and analysis on the global ovarian cancer therapeutics market. The report provi more

• Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline

  GBI Research, the leading business intelligence provider, has released its latest research, “Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline” which provides insights into the global oncology pipeline. The re more

• Global Ovarian Cancer Drugs Market 2011-2015

  TechNavio's analysts forecast the Global Ovarian Cancer Drugs market to grow at a CAGR of 13.1 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increasing prevalence of ovarian cancer. The Global Ovarian Cancer Drugs market has also been witnessing more

Websites Ovarian Cancer